Seattle Genetics CEO Clay Siegall: An Interview With “The Pink Sheet” DAILY (Part 2 Of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech chief exec addresses Seattle Genetics’ commercialization strategy and foray outside of oncology.
You may also be interested in...
Seattle Genetics Moves Antibody-Drug Conjugate Into Phase III For Hodgkin’s Lymphoma
SGN-35 trial kicks off in first quarter under a special protocol assessment, with an NDA filing targeted for 2011.
Seattle Genetics Moves Antibody-Drug Conjugate Into Phase III For Hodgkin’s Lymphoma
SGN-35 trial kicks off in first quarter under a special protocol assessment, with an NDA filing targeted for 2011.
Seattle Genetics CEO Clay Siegall: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)
Biotech chief exec sits down to talk about the comprehensive development program for SGN-40 in cancer and partnering with Genentech.